Sort
30,917 grants matching “tumor microenvironment”
Computational Methods for Identifying Non-coding Cancer Drivers
$721,394Ekta Khurana · Weill Medical Coll Of Cornell Univ · R01 · FY2020 · CA
Novel Markers for Disease Outcome in Breast Cancer
$721,279Stefan Ambs · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA
Molecular Determinants of Inflammatory Breast Cancer
$721,200Gayathri Devi · Duke University · R01 · FY2025 · CA
Personalized vaccine for patients with AML
$721,179David E Avigan · Beth Israel Deaconess Medical Center · R01 · FY2020 · CA
Personalized vaccine for patients with AML
$721,179David E Avigan · Beth Israel Deaconess Medical Center · R01 · FY2018 · CA
Improving risk allocation and developing novel therapies for children with T-ALL and T-LL
$721,069David T. Teachey · Children'S Hosp Of Philadelphia · R01 · FY2024 · CA
Small-molecule exploitation of ZBP1-driven nuclear necroptosis for cancer immunotherapy
$721,035Siddharth Balachandran · Research Inst Of Fox Chase Can Ctr · R01 · FY2024 · CA
Molecular and immunologic evolution of melanomas from pre-neoplastic lesions
$720,975Boris C Bastian · University Of California, San Francisco · R35 · FY2017 · CA
JOC-x: Chemotherapy conjugates that open tumor tight junctions to treat cancer
$720,945Darrick Albert Carter · Pai Life Sciences, Inc. · R44 · FY2019 · CA
Role of FACT in ZFTA-RelA fusion driven ependymoma
$720,877Monica Venere · Ohio State University · R01 · FY2023 · CA
Advancing the translatability of mouse models for cancer immunotherapy
$720,801Rosemary J Akhurst · University Of California, San Francisco · R01 · FY2020 · CA
Tumor Growth and Microenvironment Influence T Cell Tolerance to Tumor Antigens
$720,716Arthur Hurwitz · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA
DEFINING THE IMPACT OF KRAS MUTATIONAL HETEROGENEITY ON THE TUMOR MICROENVIRONMENT IN PANCREATIC CANCER
$720,375Weill Medical College Of Cornell University · · FY2025 · Defense Health Agency
Mechanism of action and therapeutic utility of stimulatory CpG oligonucleotides
$720,328Dennis Klinman · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Determining the Impact of Metabolic Adaptations on the Immune-Tumor Microenvironment in Metastatic Breast Cancer
$719,799Subhamoy Dasgupta · Roswell Park Cancer Institute Corp · R01 · FY2025 · CA
Preclinical development of breakthrough immunotherapy for brain tumors
$719,525Hideho Okada · University Of California, San Francisco · R35 · FY2019 · NS
Enhancing B7-H3-CAR T cell therapy for pediatric solid tumors
$719,445Christopher C. Derenzo · St. Jude Children'S Research Hospital · R01 · FY2023 · CA
Elucidating the role of transcriptomics in driving ethnicity and ancestry-related disparities in colorectal cancer
$719,426Jane C. Figueiredo · Cedars-Sinai Medical Center · R01 · FY2024 · CA
A Unique Class of Reductively Activated Oncology Drugs
$718,986Dale L Boger · Scripps Research Institute, The · R01 · FY2021 · CA
A Unique Class of Reductively Activated Oncology Drugs
$718,986Dale L Boger · Scripps Research Institute, The · R01 · FY2017 · CA
A Unique Class of Reductively Activated Oncology Drugs
$718,986Dale L Boger · Scripps Research Institute, The · R01 · FY2020 · CA
Clinical and Translational Investigations of Immune Suppression and Immune Modulation in Glioblastoma
$718,983Edjah Nduom · National Institute Of Neurological Disorders And Stroke · ZIA · FY2023 · NS
Molecular Phenotypes within and across disease boundaries in IPF and COPD
$718,962Naftali Kaminski · University Of Pittsburgh At Pittsburgh · R01 · FY2010 · HL
Imaging tumor and T cell responses to metabolic and immune modulation therapy
$718,818Ronald G Blasberg · Sloan-Kettering Inst Can Research · R01 · FY2019 · CA
Transformed Epithelial Cells and Activated Fibroblasts in the Esopheageal Tumor M
$718,803Anil K Rustgi · University Of Pennsylvania · P01 · FY2009 · CA